KAZIA THERAPEUTICS Business Summary

Kazia Therapeutics Ltd (KZIA) is a clinical-stage oncology biotechnology company that generates revenue primarily through strategic licensing agreements, research collaborations, and milestone payments. The company’s business model is centered on the development and commercialization of high-value, targeted cancer therapies, specifically focusing on its lead program, paxalisib—a brain-penetrant PI3K/mTOR inhibitor targeting glioblastoma, DIPG, and brain metastases—and EVT801, a selective VEGFR3 inhibitor for advanced solid tumors. Kazia operates within the specialized neuro-oncology and metastatic cancer segments, positioning itself as a niche developer of therapies capable of crossing the blood-brain barrier. It competes directly with oncology-focused firms such as Nimbus Therapeutics, Blueprint Medicines, Mereo BioPharma, and Imugene Limited, distinguishing itself through its advanced clinical data in rare pediatric and adult brain cancers. Leadership is spearheaded by CEO Dr. John Friend, a Rutgers-educated physician with over 25 years of experience in oncology drug development, including senior roles at Helsinn Therapeutics and Cellectar Biosciences. The board is chaired by Bryce Carmine, a former Executive Vice President at Eli Lilly & Co. with nearly four decades of pharmaceutical leadership. Other key executives include Jeffrey Bonacorda, VP of Finance and Controller, who brings 30 years of industry experience. The company’s strategic direction is supported by a board featuring Robert Apple, former CEO of Antares Pharma, and is backed by a robust institutional investor base following a $50 million private placement in late 2025 led by healthcare-dedicated funds including Adar1 Capital Management, Ikarian Capital, and Stonepine Capital Management.